Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
γδ T cell therapy is an ideal approach for cancer immunotherapy. Empowered by leading technology and years of experience in cellular therapy solutions, Creative Biolabs is now dedicated to developing NSCAR-γδ T cell services.
CAR-T therapy is successful immunotherapy in hematological tumors but limited in solid tumors. CAR- γδ T cells is an alternative approach to improve CAR-T therapy. CARs commonly consist of an extracellular antigen-binding domain that is most commonly a single-chain variable fragment (scFv) of a mAb linked to intracellular signaling components such as CD3ζ alone or combined with one or more costimulatory domains. Appropriate compositional and structural design of CARs can reduce off-target effects and enhance tumor eradication and persistence.
Fig.1 Chimeric antigen receptor (CAR) design: conventional CARs (a), adaptor CAR systems (b), and efficacy of adaptor CAR.1
A strategy of the structural design of CARs is to design non-signaling CARs (NSCARs). NSCARs lack the intracellular signaling domains typically present in a CAR. NSCARs are non-activating in αβ T cells and don't enhance αβ T cell cytotoxicity against tumor cells. Unlike αβ T cells, NSCARs are introduced into γδ T cells to enhance target cell killing, because γδ T cells possess alternative mechanisms of cytotoxicity such as NKG2D engagement, Fas-FasL interactions, and do not require stimulation through CD3ζ in order to initiate target cell killing. NSCARs expressed on the surface of γδ T cells specifically recognize tumor antigens and provide direction towards tumor cells. While the cells are in close proximity, the cytotoxic mechanisms endogenous to γδ T cells can engage, ultimately resulting in tumor cell death.
With our CAR development platform and advanced technologies, Creative Biolabs provides CAR design and construction services specific for a variety of target antigens. If you are interested in our services, please feel free to contact us.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
